Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients

Nephrology

Volumn 16, Issue 3, 2011, Pages 299-303

  Nagano, Makio ^a   Fukami, Kei ^a   Yamagishi, Sho Ichi ^b   Sakai, Kazuko ^a   Kaida, Yusuke ^a   Matsumoto, Takafumi ^a   Hazama, Takuma ^a   Tanaka, Masahiro ^a   Ueda, Seiji ^a   Okuda, Seiya ^a  

^a Division of Nephrology   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

advanced glycation end products; atherosclerosis; haemodialysis; inflammation

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ADVANCED GLYCATION END PRODUCT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CREATININE; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; SERUM ALBUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; URIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; AUTOFLUORESCENCE; BLOOD VESSEL PARAMETERS; CAROTID ARTERY; CORRELATION ANALYSIS; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; FEMALE; GROUPS BY AGE; HEMODIALYSIS PATIENT; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULSATILITY INDEX; SKIN; TISSUE LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PULSATILE FLOW; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SKIN; ULTRASONOGRAPHY, DOPPLER; UP-REGULATION;

EID: 79951974363     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01419.x     Document Type: Article

References (32)

1. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 108-20. (Pubitemid 38072622)
2. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG,. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J. Am. Soc. Nephrol. 2003; 14: 415-24. (Pubitemid 36150865)
3. Bevc S, Sabic S, Hojs R,. Atherosclerosis in hemodialysis patients-the role of microinflammation. Ren. Fail. 2008; 30: 1012-16.
4. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C,. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-58. (Pubitemid 29082891)
5. Piroddi M, Depunzio I, Calabrese V, et al. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007; 32: 573-92. (Pubitemid 46790939)
6. Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J. Am. Soc. Nephrol. 2003; 14: 1614-22. (Pubitemid 36687064)
7. Yu TM, Chen YH, Hsu JY, et al. Systemic inflammation is associated with pulmonary hypertension in patients undergoing haemodialysis. Nephrol. Dial. Transplant. 2009; 24: 1946-51.
8. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C,. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am. J. Kidney Dis. 2009; 54: 902-11.
9. Cai W, Zhu L, Chen X, Uribarri J, Peppa M,. Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients. Am. J. Nephrol. 2006; 26: 181-5. (Pubitemid 43882403)
10. Brownlee M, Cerami A, Vlassara H,. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988; 318: 1315-21.
11. Grandhee SK, Monnier VM,. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J. Biol. Chem. 1991; 266: 11649-53. (Pubitemid 21906998)
12. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW,. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991; 266: 11654-60. (Pubitemid 21906999)
13. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 1991; 325: 836-42.
14. Vlassara H,. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46 (Suppl 2): S19-25. (Pubitemid 27377393)
15. Nakamura T, Sato E, Fujiwara N, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009; 58: 1624-8.
16. Yamagishi S,. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther. Apher. Dial. 2009; 13: 534-9.
17. Kilhovd BK, Juutilainen A, Lehto S, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 815-20. (Pubitemid 40463875)
18. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007; 50: 1409-17. (Pubitemid 46879016)
19. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29: 2654-9. (Pubitemid 44912194)
20. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005; 16: 3687-93. (Pubitemid 46211290)
21. Yamada S, Inaba M, Kurajoh M, et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin. Endocrinol. (Oxf.) 2008; 69: 189-96. (Pubitemid 352009021)
22. Daugirdas JT,. Linear estimates of variable-volume, single-pool Kt/V: an analysis of error. Am. J. Kidney Dis. 1993; 22: 267-70. (Pubitemid 23236633)
23. Gosling RG, King DH,. Arterial assessment by Doppler-shift ultrasound. Proc. R. Soc. Med. 1974; 67: 447-9.
24. Matsumoto T, Tsurumoto T, Baba H, et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol. Int. 2007; 28: 157-60. (Pubitemid 350105869)
25. Arsov S, Graaff R, Morariu AM, et al. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Nephrol. Dial. Transplant. 2009.
26. Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006; 49: 3094-9. (Pubitemid 44730314)
27. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J,. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27: 223-8. (Pubitemid 38196736)
28. Nakatou T, Nakata K, Nakamura A, Itoshima T,. Carotid haemodynamic parameters as risk factors for cerebral infarction in Type 2 diabetic patients. Diabet. Med. 2004; 21: 223-9. (Pubitemid 38299615)
29. Mulder DJ, van Haelst PL, Gross S, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008; 197: 217-23. (Pubitemid 351273241)
30. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-911. (Pubitemid 29197978)
31. Eleftheriadis T, Kartsios C, Antoniadi G, et al. The impact of chronic inflammation on bone turnover in hemodialysis patients. Ren. Fail. 2008; 30: 431-7. (Pubitemid 351868698)
32. Mulder DJ, Water TV, Lutgers HL, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol. Ther. 2006; 8: 523-35. (Pubitemid 44946877)